Ullah W, Zghouzi M, Ahmad B, et al. - Because there exists a controversy regarding the relative safety as well as efficacy of aspirin vs dual antiplatelet therapy (DAPT; aspirin+clopidogrel) among patients who received transcatheter aortic valve implantation (TAVI) and did not have a long-term indication for oral anticoagulation, researchers explored this topic by analyzing relevant articles that were identified from digital databases. Bleeding was the major safety endpoint, and post-TAVI ischemic and thrombotic events were reported as the efficacy endpoints. The quantitative analysis was performed with 11 studies including 4,805 patients (aspirin 2258, DAPT 2547). Significantly lower odds of all cause bleeding, major vascular bleeding, Valve Academic Research Consortium 2 (VARC-2) major bleeding, VARC-2 minor bleeding, transfusion need and major vascular complications were found in patients receiving aspirin-alone vs post-TAVI patients treated with both aspirin and clopidogrel. Overall, findings revealed lower bleeding events in post-TAVI patients treated with aspirin alone, with no significant differences in death and stroke rate vs those managed with DAPT.